Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Last updated: September 18, 2017
Sponsor: Bayer
Overall Status: Active - Recruiting

Phase

1

Condition

Mesothelioma

Non-small Cell Lung Cancer

Treatment

BAY 94-9343

cisplatin

Pemetrexed

Clinical Study ID

NCT02639091
2016-003988-18
  • Ages 18-100
  • All Genders

Study Summary

Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.

Study Design

Total Participants: 30
Treatment Group(s): 3
Primary Treatment: BAY 94-9343
Phase: 1
Study Start date:
Estimated Completion Date:

Study Description